ABBOTT Laboratories actions jumped on Wednesday after the diversified medical care company delivered strong results of the first quarter and left its gain guide intact, a large sign of confidence at an uncertain moment. Income in the three months ended on March 31 increased 4% to $ 10.36 billion, losing the consensus of $ 10.4 billion, according to estimates compiled by LSE. Organic sales, excluding the results of COVID tests, increased by 8.3%, exceeding 7.7%estimate, according to FACTSET. The profits adjusted by Action (EPS) increased 11.2% annually to $ 1.09, which exceeded expectations in 2 cents, showed the LSE data. ABT YTD MOUNTAIN ABBOTT LABORATORIES YTD ABBOTT's Ganing Rally extends what has already been a good year for actions in a Brutal General Market. Abbott's actions entered Wednesday's session as the second best action of the club, advancing 11.6%. Only Crowdstrike, with a gain of 14.8%, had done better. Abbott has also significantly exceeded a basket of medical devices this year. In a nutshell, Abbott became an excellent room in a difficult atmosphere with tariffs. The company exceeded the expectations of Wall Street in its three main profitability metrics (earnings per share, adjusted gross margin and margin of income before adjusted taxes, while offering a better organic sales growth that expected to exclude the COVID test Diagnosis, which faces pressures out of control; “Out of China this quarter, we grew around 7%.” Abbott is looking for ways to enliven growth in other geographies to compensate for realities to do business in China, Ford said. “We are just going to have to go through this. [China] It is still an important market. It still has good profitability. “Abbott Laboratories why we possess it: ABBOTT is a high quality medical technology company that grows in a fast clip for its industry. The action has treated several blasting ones, since we have owned it, such as the concerns of litigation linked to its specialized formula of the children May 2024 Initiated: January 29, 2024 The cherry at the top of the quarter was that Abbott reaffirmed its 2025 profit guide from $ 5.05 to $ 5.25 per share despite a considerably different tariff image that at the end of January at the end of January. which generates approximately two thirds of its income abroad. “But the tariffs are here, so we feel that reaffirming our guide is already a fairly strong statement.” We agree. For that reason, we are reiterating our target price of $ 145 per share, it is not a small feat in a market where the PT from left to right are cut, and maintaining our rating of 2 equivalents in the shares. We know that Abbott's tariff exposure is marginal, and has other drivers to compensate for those winds against. ABBOTT could be an action to buy if we see another day in which tariff holders reduce the entire stock market. Comment The previous picture illustrates the quality of the Abbott neighborhood. The diagnosis was the only one of Abbott's four reports that failed in sales, but as discussed, it is not a material concern. Nutrition, brands of brands such as guaranteeing powdered proteins and pediasure drinks for children, exceeded expectations, and Ford said that the company is progressing in the recovery of market share that lost a few rooms ago due to execution fathers. Sales in established pharmaceutical products, its generic business business that only operates internationally, also arrived better than expected. The medical devices, their largest and most important segment, provided a strong growth year after year, 9.9% more informed and 12.6% organically, which excludes winds against foreign exchange. In its rapid diabetes portfolio, the sales of continuous glucose monitors, or CGMS, totaled $ 1.7 billion in the first quarter, more than 20% year after year and 30% in the US. As for tariffs, Ford also mentioned that Abbott has two manufacturing sites for free in the United States to serve customers in their local market. Another important product for Abbott is its Volt PFA system, which in March assured an approval prior to the expected European regulators. Volt, which is used to treat abnormal heart rhythms, helps Abbott to compete against the tastes of Boston Scientific and Medtronic in the pulsed field ablation devices market (PFA). The inherited way of treating conditions such as atrial fibrillation used extreme heat (radiofrequency ablation) or cold (cryoablation). PFA devices, on the contrary, use an electrical pulse to destroy cells that cause abnormal heart rhythms, an approach that is announced as safer and faster than traditional treatment options. ABBOTT plans to present for the approval of the United States for Volt at the end of this year, with the authorization possibly in early 2026. “The initial feedback that my team has shared with me has been very, very positive,” Ford said about the launch of Volt in Europe. “Obviously, we will begin with a deployment where we will focus a little on the users who were part of our clinical trial, and then we will begin to increase that as we move forward in the second half of the year.” He added: “I think the product will work very well. I think what we intend to do.” Abbott's effort to throw an outstanding litigation of his actions suffered a setback during the first quarter, although our belief will only be temporary. In mid -March, a judge in Missouri ordered a new trial in a case that Abbott and his Rekitt rival won in November, overcoming accusations that their specialized formulas for premature babies caused a serious intestinal disease known as necrotizing enterocolitis, or NEC. ABBOTT has said that the re-tax ruling will appeal, which was based on the alleged misconduct of the lawyers of the accused during the initial procedures. Executives really did not discuss NEC procedures in the call, apart from saying that it does not influence the way they are evaluating their entire business. The main conclusion here: Abbott's NEC litigation has not disappeared, but we continue to believe that the risks are much more manageable than the market estimated before. (Jim Cramer's charitable trust is long. See a complete list of actions here). As a subscriber of the CNBC Investing Club with Jim Cramer, he will receive a commercial alert before Jim makes an exchange. Jim waits 45 minutes after sending a commercial alert before buying or selling an action in the portfolio of his charitable trust. If Jim has talked about an action on CNBC TV, wait 72 hours after issuing the trade alert before executing the operation. The information of the previous investment club is subject to our terms and conditions and privacy policy, together with our discharge of responsibility. There is no fiduciary obligation or duty, or is created, by virtue of receiving any information provided in relation to the investment club. No specific results or profits are guaranteed.
The president of the Board and CEO of Abbott, Robert B. Ford, offers an opening speech at CES 2022 at Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada.
Ethan Miller | Getty images
Actions of ABBOTT laboratories He jumped on Wednesday after the diversified medical care company delivered strong results of the first quarter and left his profit guide intact, a large confidence signal at an uncertain moment.
